{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:38:21Z","timestamp":1782261501284,"version":"3.54.5"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["48363.01"],"award-info":[{"award-number":["48363.01"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Accurate measurement of anti-malarial drug concentrations in therapeutic efficacy studies is essential to distinguish between inadequate drug exposure and anti-malarial drug resistance, and to inform optimal anti-malarial dosing in key target population groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A sensitive and selective LC\u2013MS\/MS method was developed and validated for the simultaneous determination of amodiaquine and its active metabolite, desethylamodiaquine, and used to describe their pharmacokinetic parameters in Ghanaian patients with uncomplicated falciparum malaria treated with the fixed-dose combination, artesunate-amodiaquine.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The day-28 genotype-adjusted adequate clinical and parasitological response rate in 308 patients studied was\u2009&gt;\u200997% by both intention-to-treat and per-protocol analysis. After excluding 64 patients with quantifiable amodiaquine concentrations pre-treatment and 17 with too few quantifiable concentrations, the pharmacokinetic analysis included 227 patients (9 infants, 127 aged 1\u20134\u00a0years, 91 aged\u2009\u2265\u20095\u00a0years). Increased median day-3 amodiaquine concentrations were associated with a lower risk of treatment failure [HR 0.87 (95% CI 0.78\u20130.98), p\u2009=\u20090.021]. Amodiaquine exposure (median AUC<jats:sub>0-\u221e<\/jats:sub>) was significantly higher in infants (4201\u00a0ng\u00a0h\/mL) and children aged 1\u20135\u00a0years (1994\u00a0ng\u00a0h\/mL) compared to older children and adults (875\u00a0ng\u00a0h\/mL, p\u2009=\u20090.001), even though infants received a lower mg\/kg amodiaquine dose (median 25.3 <jats:italic>versus<\/jats:italic> 33.8\u00a0mg\/kg in older patients). Desethylamodiaquine AUC<jats:sub>0-\u221e<\/jats:sub> was not significantly associated with age. No significant safety concerns were identified.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Efficacy of artesunate-amodiaquine at currently recommended dosage regimens was high across all age groups. Reassuringly, amodiaquine and desethylamodiaquine exposure was not reduced in underweight-for-age young children or those with high parasitaemia, two of the most vulnerable target populations. A larger pharmacokinetic study with close monitoring of safety, including full blood counts and liver function tests, is needed to confirm the higher amodiaquine exposure in infants, understand any safety implications and assess whether dose optimization in this vulnerable, understudied population is needed.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12936-020-03553-6","type":"journal-article","created":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T21:03:31Z","timestamp":1609967011000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Pharmacokinetic profile of amodiaquine and its active metabolite desethylamodiaquine in Ghanaian patients with uncomplicated falciparum malaria"],"prefix":"10.1186","volume":"20","author":[{"given":"Thomas A.","family":"Anyorigiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Castel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katya","family":"Mauff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Atuguba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhards","family":"Ogutu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Oduro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dosoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwaku-Poku","family":"Asante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Owusu-Agyei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Dodoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Hodgson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Binka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley J.","family":"Workman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth N.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Denti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubbe","family":"Wiesner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0107-3063","authenticated-orcid":false,"given":"Karen I.","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,6]]},"reference":[{"key":"3553_CR1","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/nm.3077","volume":"19","author":"PL Alonso","year":"2013","unstructured":"Alonso PL, Tanner M. Public health challenges and prospects for malaria control and elimination. Nat Med. 2013;19:150\u20135.","journal-title":"Nat Med"},{"key":"3553_CR2","unstructured":"WHO. World malaria report 2019. Geneva: World Health Organization; 2019. https:\/\/www.who.int\/publications\/i\/item\/9789241565721. Accessed 5 Nov 2020."},{"key":"3553_CR3","unstructured":"WHO. Guidelines for the treatment of malaria. 3rd Edn. Geneva: World Health Organization; 2015. https:\/\/www.who.int\/docs\/default-source\/documents\/publications\/gmp\/guidelines-for-the-treatment-of-malaria-eng.pdf?sfvrsn=a0138b77_2. Accessed 5 Nov 2020."},{"key":"3553_CR4","unstructured":"Ghana Ministry of Health. Anti-Malaria Drug Policy for Ghana. Ministry of Health; 2009. https:\/\/www.ghanahealthservice.org\/downloads\/GHS_Antimalaria_drug_policy.pdf. Accessed 5 Nov 2020."},{"key":"3553_CR5","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.actatropica.2005.06.018","volume":"95","author":"KA Koram","year":"2005","unstructured":"Koram KA, Abuaku B, Duah N, Quashie N. Comparative efficacy of antimalarial drugs including ACTs in the treatment of uncomplicated malaria among children under 5 years in Ghana. Acta Trop. 2005;95:194\u2013203.","journal-title":"Acta Trop"},{"key":"3553_CR6","first-page":"55","volume":"42","author":"K Koram","year":"2008","unstructured":"Koram K, Quaye L, Abuaku B. Efficacy of amodiaquine\/artesunate combination therapy for uncomplicated malaria in children under five years in Ghana. Ghana Med J. 2008;42:55\u201360.","journal-title":"Ghana Med J"},{"key":"3553_CR7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/1475-2875-7-127","volume":"7","author":"GO Adjei","year":"2008","unstructured":"Adjei GO, Kurtzhals JAL, Rodrigues OP, Alifrangis M, Hoegberg LCG, Kitcher ED, et al. Amodiaquine-artesunate vs artemether-lumefantrine for uncomplicated malaria in Ghanaian children: a randomized efficacy and safety trial with one year follow-up. Malar J. 2008;7:127.","journal-title":"Malar J"},{"key":"3553_CR8","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1179\/136485908X337508","volume":"102","author":"AR Oduro","year":"2008","unstructured":"Oduro AR, Anyorigiya T, Anto F, Amenga-Etego L, Ansah NA, Atobrah P, et al. A randomized, comparative study of supervised and unsupervised artesunate-amodiaquine, for the treatment of uncomplicated malaria in Ghana. Ann Trop Med Parasitol. 2008;102:565\u201376.","journal-title":"Ann Trop Med Parasitol"},{"key":"3553_CR9","doi-asserted-by":"publisher","first-page":"e2530","DOI":"10.1371\/journal.pone.0002530","volume":"3","author":"S Owusu-Agyei","year":"2008","unstructured":"Owusu-Agyei S, Asante KP, Owusu R, Adjuik M, Amenga-Etego S, Dosoo DK, et al. An open label, randomised trial of artesunate+amodiaquine, artesunate+chlorproguanil-dapsone and artemether-lumefantrine for the treatment of uncomplicated malaria. PLoS ONE. 2008;3:e2530.","journal-title":"PLoS ONE"},{"key":"3553_CR10","doi-asserted-by":"publisher","first-page":"690","DOI":"10.4269\/ajtmh.15-0826","volume":"97","author":"BK Abuaku","year":"2017","unstructured":"Abuaku BK, Mensah BA, Ofori MF, Myers-Hansen J, Derkyi-Kwarteng AN, Essilfie F, et al. Efficacy of artesunate\/amodiaquine in the treatment of uncomplicated malaria among children in Ghana. Am J Trop Med Hyg. 2017;97:690\u20135.","journal-title":"Am J Trop Med Hyg"},{"key":"3553_CR11","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/1475-2875-8-189","volume":"8","author":"JA Simpson","year":"2009","unstructured":"Simpson JA, Jamsen KM, Price RN, White NJ, Lindegardh N, Tarning J, et al. Towards optimal design of anti-malarial pharmacokinetic studies. Malar J. 2009;8:189.","journal-title":"Malar J"},{"key":"3553_CR12","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.pt.2007.11.008","volume":"24","author":"KI Barnes","year":"2008","unstructured":"Barnes KI, Watkins WM, White NJ. Antimalarial dosing regimens and drug resistance. Trends Parasitol. 2008;24:127\u201334.","journal-title":"Trends Parasitol"},{"key":"3553_CR13","first-page":"CD000016","volume":"2","author":"PL Olliaro","year":"2003","unstructured":"Olliaro PL, Mussano P. Amodiaquine for treating malaria. Cochrane Database Syst Rev. 2003;2:CD000016.","journal-title":"Cochrane Database Syst Rev."},{"key":"3553_CR14","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/1475-2875-8-203","volume":"8","author":"J Zwang","year":"2009","unstructured":"Zwang J, Olliaro P, Barennes H, Bonnet M, Brasseur P, Bukirwa H, et al. Efficacy of artesunate-amodiaquine for treating uncomplicated falciparum malaria in sub-Saharan Africa: a multi-centre analysis. Malar J. 2009;8:203.","journal-title":"Malar J"},{"key":"3553_CR15","doi-asserted-by":"publisher","first-page":"e1000407","DOI":"10.1371\/journal.pmed.1000407","volume":"8","author":"A Dicko","year":"2011","unstructured":"Dicko A, Diallo AI, Tembine I, Dicko Y, Dara N, Sidibe Y, et al. Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Mali: a randomised, double-blind, placebo-controlled trial. PLoS Med. 2011;8:e1000407.","journal-title":"PLoS Med"},{"key":"3553_CR16","doi-asserted-by":"publisher","first-page":"e0162563","DOI":"10.1371\/journal.pone.0162563","volume":"11","author":"JL Ndiaye","year":"2016","unstructured":"Ndiaye JL, Ciss\u00e9 B, Ba EH, Gomis JF, Ndour CT, Molez JF, et al. Safety of seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine plus amodiaquine when delivered to children under 10 years of age by district health services in Senegal: results from a stepped-wedge cluster randomized trial. PLoS ONE. 2016;11:e0162563.","journal-title":"PLoS ONE"},{"key":"3553_CR17","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1365-2125.1990.tb03690.x","volume":"29","author":"PA Winstanley","year":"1990","unstructured":"Winstanley PA, Simooya O, Kofi-Ekue JM, Walker O, Salako LA, Edwards G, et al. The disposition of amodiaquine in Zambians and Nigerians with malaria. Br J Clin Pharmacol. 1990;29:695\u2013701.","journal-title":"Br J Clin Pharmacol"},{"key":"3553_CR18","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/j.1365-2125.2004.02257.x","volume":"59","author":"FW Hombhanje","year":"2005","unstructured":"Hombhanje FW, Hwaihwanje I, Tsukahara T, Saruwatari J, Nakagawa M, Osawa H, et al. The disposition of oral amodiaquine in Papua New Guinean children with falciparum malaria. Br J Clin Pharmacol. 2005;59:298\u2013301.","journal-title":"Br J Clin Pharmacol"},{"key":"3553_CR19","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s10928-007-9064-2","volume":"34","author":"SF Hietala","year":"2007","unstructured":"Hietala SF, Bhattarai A, Msellem M, R\u00f6shammar D, Ali AS, Str\u00f6mberg J, et al. Population pharmacokinetics of amodiaquine and desethylamodiaquine in pediatric patients with uncomplicated falciparum malaria. J Pharmacokinet Pharmacodyn. 2007;34:669\u201386.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"3553_CR20","doi-asserted-by":"publisher","first-page":"4400","DOI":"10.1128\/AAC.00673-07","volume":"52","author":"GO Adjei","year":"2008","unstructured":"Adjei GO, Kristensen K, Goka BQ, Hoegberg LCG, Alifrangis M, Rodrigues OP, et al. Effect of concomitant artesunate administration and cytochrome P4502C8 polymorphisms on the pharmacokinetics of amodiaquine in Ghanaian children with uncomplicated malaria. Antimicrob Agents Chemother. 2008;52:4400\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"3553_CR21","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/1475-2875-8-200","volume":"8","author":"K Stepniewska","year":"2009","unstructured":"Stepniewska K, Taylor W, Sirima SB, Ouedraogo EB, Ouedraogo A, Gansan\u00e9 A, et al. Population pharmacokinetics of artesunate and amodiaquine in African children. Malar J. 2009;8:200.","journal-title":"Malar J"},{"key":"3553_CR22","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1128\/AAC.00679-09","volume":"54","author":"J Mwesigwa","year":"2010","unstructured":"Mwesigwa J, Parikh S, McGee B, German P, Drysdale T, Kalyango JN, et al. Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala Uganda. Antimicrob Agents Chemother. 2010;54:52\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"3553_CR23","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1128\/AAC.01496-09","volume":"54","author":"V Jullien","year":"2010","unstructured":"Jullien V, Ogutu B, Juma E, Carn G, Obonyo C, Kiechel JR. Population pharmacokinetics and pharmacodynamic considerations of amodiaquine and desethylamodiaquine in Kenyan adults with uncomplicated malaria receiving artesunate-amodiaquine combination therapy. Antimicrob Agents Chemother. 2010;54:2611\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"3553_CR24","unstructured":"WHO. Methods and techniques for assessing exposure to antimalarial drugs in clinical field studies: informal consultation organized by the World Health Organization with the technical support of the WorldWide Antimalarial Resistance Network. Geneva: World Health Organization; 2011. https:\/\/www.who.int\/docs\/default-source\/documents\/publications\/gmp\/methods-and-techniques-for-assessing-exposure-to-antimalarial-drugs-in-clinical-field-studies.pdf?sfvrsn=7a2a8c942. Accessed 5 Nov 2020"},{"key":"3553_CR25","first-page":"884","volume":"280","author":"DJ Naisbitt","year":"1997","unstructured":"Naisbitt DJ, Ruscoe JE, Williams D, O\u2019Neill PM, Pirmohamed M, Park BK. Disposition of amodiaquine and related antimalarial agents in human neutrophils: implications for drug design. J Pharmacol Exp Ther. 1997;280:884\u201393.","journal-title":"J Pharmacol Exp Ther"},{"key":"3553_CR26","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/S0378-4347(00)83258-2","volume":"374","author":"E Pussard","year":"1986","unstructured":"Pussard E, Verdier F, Blayo MC. Simultaneous determination of chloroquine, amodiaquine and their metabolites in human plasma, red blood cells, whole blood and urine by column liquid chromatography. J Chromatogr. 1986;374:111\u20138.","journal-title":"J Chromatogr"},{"key":"3553_CR27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/BF02492307","volume":"55","author":"N Lindeg\u00e5rdh","year":"2002","unstructured":"Lindeg\u00e5rdh N, Forslund M, Green MD, Kaneko A, Bergqvist Y. Automated solid-phase extraction for determination of amodiaquine, chloroquine and metabolites in capillary blood on sampling paper by liquid chromatography. Chromatographia. 2002;55:5\u201312.","journal-title":"Chromatographia"},{"key":"3553_CR28","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jchromb.2003.10.006","volume":"799","author":"EN Gitau","year":"2004","unstructured":"Gitau EN, Muchohi SN, Ogutu BR, Githiga IM, Kokwaro GO. Selective and sensitive liquid chromatographic assay of amodiaquine and desethylamodiaquine in whole blood spotted on filter paper. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;799:173\u20137.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"3553_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2125.1987.tb03002.x","volume":"23","author":"P Winstanley","year":"1987","unstructured":"Winstanley P, Edwards G, Orme M, Breckenridge A. The disposition of amodiaquine in man after oral administration. Br J Clin Pharmacol. 1987;23:1\u20137.","journal-title":"Br J Clin Pharmacol"},{"key":"3553_CR30","unstructured":"WHO. Methods for surveillance of antimalarial drug efficacy. Geneva, World Health Organization; 2009 http:\/\/whqlibdoc.who.int\/publications\/2009\/9789241597531_eng.pdf. Accessed 5 Nov 2020"},{"key":"3553_CR31","doi-asserted-by":"publisher","first-page":"565","DOI":"10.4269\/ajtmh.1995.52.565","volume":"52","author":"CV Plowe","year":"1995","unstructured":"Plowe CV, Djimde A, Bouare M, Doumbo O, Wellems TE. Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am J Trop Med Hyg. 1995;52:565\u20138.","journal-title":"Am J Trop Med Hyg"},{"key":"3553_CR32","unstructured":"WHO. Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations: informal consultation organized by the Medicines for Malaria Venture and cosponsored by the World Health Organization, 29\u201331 May 2007, Amsterdam, The Netherlands, 2008. http:\/\/apps.who.int\/iris\/bitstream\/10665\/43824\/1\/9789241596305_eng.pdf. Accessed 5 Nov 2020"},{"key":"3553_CR33","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S0035-9203(97)90539-3","volume":"91","author":"LC Ranford-Cartwright","year":"1997","unstructured":"Ranford-Cartwright LC, Taylor J, Umasunthar T, Taylor LH, Babiker HA, Lell B, et al. Molecular analysis of recrudescent parasites in a Plasmodium falciparum drug efficacy trial in Gabon. Trans R Soc Trop Med Hyg. 1997;91:719\u201324.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"3553_CR34","unstructured":"Food and Drug Administration. Guidance for Industry Bioanalytical Method Validation. 2001. http:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/ucm070107.pdf. Accessed 5 Nov 2020"},{"key":"3553_CR35","doi-asserted-by":"publisher","first-page":"e8988","DOI":"10.1371\/journal.pone.0008988","volume":"5","author":"I Carneiro","year":"2010","unstructured":"Carneiro I, Roca-Feltrer A, Griffin JT, Smith L, Tanner M, Schellenberg JA, et al. Age-patterns of malaria vary with severity, transmission intensity and seasonality in sub-Saharan Africa: a systematic review and pooled analysis. PLoS ONE. 2010;5:e8988.","journal-title":"PLoS ONE"},{"key":"3553_CR36","unstructured":"WHO. Child growth standards: length\/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age; methods and development. Geneva: World Health Organization; 2006. https:\/\/www.who.int\/childgrowth\/standards\/technical_report\/en\/. Accessed 5 Nov 2020"},{"key":"3553_CR37","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.clpt.2006.08.016","volume":"80","author":"K Barnes","year":"2006","unstructured":"Barnes K, Little F, Smith P, Evans A, Watkins W, White N. Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. Clin Pharmacol Ther. 2006;80:582\u201396.","journal-title":"Clin Pharmacol Ther"},{"key":"3553_CR38","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/1475-2875-5-59","volume":"5","author":"F Checchi","year":"2006","unstructured":"Checchi F, Piola P, Fogg C, Bajunirwe F, Biraro S, Grandesso F, et al. Supervised versus unsupervised antimalarial treatment with six-dose artemether-lumefantrine: pharmacokinetic and dosage-related findings from a clinical trial in Uganda. Malar J. 2006;5:59.","journal-title":"Malar J"},{"key":"3553_CR39","doi-asserted-by":"publisher","first-page":"4090","DOI":"10.1128\/AAC.00486-07","volume":"51","author":"RN Price","year":"2007","unstructured":"Price RN, Hasugian AR, Ratcliff A, Siswantoro H, Purba HLE, Kenangalem E, et al. Clinical and pharmacological determinants of the therapeutic response to dihydroartemisinin-piperaquine for drug-resistant malaria. Antimicrob Agents Chemother. 2007;51:4090\u20137.","journal-title":"Antimicrob Agents Chemother"},{"key":"3553_CR40","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/1475-2875-8-52","volume":"8","author":"M Ntale","year":"2009","unstructured":"Ntale M, Obua C, Mukonzo J, Mahindi M, Gustafsson LL, Beck O, et al. Field-adapted sampling of whole blood to determine the levels of amodiaquine and its metabolite in children with uncomplicated malaria treated with amodiaquine plus artesunate combination. Malar J. 2009;8:52.","journal-title":"Malar J"},{"key":"3553_CR41","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.2165\/00003088-200645110-00003","volume":"45","author":"IH Bartelink","year":"2006","unstructured":"Bartelink IH, Rademaker CMA, Schobben AFAM, van den Anker JN. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet. 2006;45:1077\u201397.","journal-title":"Clin Pharmacokinet"},{"key":"3553_CR42","doi-asserted-by":"publisher","first-page":"e02193","DOI":"10.1128\/AAC.02193-17","volume":"62","author":"AM Ali","year":"2018","unstructured":"Ali AM, Penny MA, Smith TA, Workman L, Sasi P, Adjei GO, et al. Population pharmacokinetics of the antimalarial amodiaquine: a pooled analysis to optimize dosing. Antimicrob Agents Chemother. 2018;62:e02193-e2217.","journal-title":"Antimicrob Agents Chemother"},{"key":"3553_CR43","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1002\/cpt.1707","volume":"107","author":"J Ding","year":"2020","unstructured":"Ding J, Coldiron ME, Assao B, Guindo O, Blessborn D, Winterberg M, et al. Adherence and population pharmacokinetic properties of amodiaquine when used for seasonal malaria chemoprevention in African children. Clin Pharmacol Ther. 2020;107:1179\u201388.","journal-title":"Clin Pharmacol Ther"},{"key":"3553_CR44","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1124\/dmd.116.074583","volume":"45","author":"G Song","year":"2017","unstructured":"Song G, Sun X, Hines RN, McCarver DG, Lake BG, Osimitz TG, et al. Determination of human hepatic CYP2C8 and CYP1A2 age-dependent expression to support human health risk assessment for early ages. Drug Metab Dispos. 2017;45:468\u201375.","journal-title":"Drug Metab Dispos"},{"key":"3553_CR45","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/jcph.585","volume":"56","author":"VV Upreti","year":"2016","unstructured":"Upreti VV, Wahlstrom JL. Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling. J Clin Pharmacol. 2016;56:266\u201383.","journal-title":"J Clin Pharmacol"},{"key":"3553_CR46","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s00228-007-0452-8","volume":"64","author":"C Orrell","year":"2008","unstructured":"Orrell C, Little F, Smith P, Folb P, Taylor W, Olliaro P, et al. Pharmacokinetics and tolerability of artesunate and amodiaquine alone and in combination in healthy volunteers. Eur J Clin Pharmacol. 2008;64:683\u201390.","journal-title":"Eur J Clin Pharmacol"},{"key":"3553_CR47","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1111\/j.1365-3156.2005.01525.x","volume":"10","author":"S R\u00f6wer","year":"2005","unstructured":"R\u00f6wer S, Bienzle U, Weise A, Lambertz U, Forst T, Otchwemah RN, et al. Short communication: high prevalence of the cytochrome P450 2C8*2 mutation in Northern Ghana. Trop Med Int Health. 2005;10:1271\u20133.","journal-title":"Trop Med Int Health"},{"key":"3553_CR48","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/1471-2350-10-124","volume":"10","author":"W Kudzi","year":"2009","unstructured":"Kudzi W, Dodoo AN, Mills JJ. Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population. BMC Med Genet. 2009;10:124.","journal-title":"BMC Med Genet"},{"key":"3553_CR49","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S0140-6736(86)92371-8","volume":"1","author":"CS Hatton","year":"1986","unstructured":"Hatton CS, Peto TE, Bunch C, Pasvol G, Russell SJ, Singer CR, et al. Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. Lancet. 1986;1:411\u20134.","journal-title":"Lancet"},{"key":"3553_CR50","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1136\/bmj.292.6522.721","volume":"292","author":"KA Neftel","year":"1986","unstructured":"Neftel KA, Woodtly W, Schmid M, Frick PG, Fehr J. Amodiaquine induced agranulocytosis and liver damage. Br Med J. 1986;292:721\u20133.","journal-title":"Br Med J"},{"key":"3553_CR51","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1365-3156.2008.02190.x","volume":"14","author":"P Brasseur","year":"2009","unstructured":"Brasseur P, Agnamey P, Gaye O, Cisse M, Badiane M, Vaillant M, et al. Dosing accuracy of artesunate and amodiaquine as treatment for falciparum malaria in Casamance. Senegal Trop Med Int Health. 2009;14:79\u201387.","journal-title":"Senegal Trop Med Int Health"},{"key":"3553_CR52","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12916-015-0301-z","volume":"13","author":"WorldWide Antimalarial Resistance Network (WWARN) AS-AQ Study Group.","year":"2015","unstructured":"WorldWide Antimalarial Resistance Network (WWARN) AS-AQ Study Group. The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data. BMC Med. 2015;13:66.","journal-title":"BMC Med."},{"key":"3553_CR53","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1186\/1471-2288-13-140","volume":"13","author":"EN Allen","year":"2013","unstructured":"Allen EN, Mushi AK, Massawe IS, Vestergaard LS, Lemnge M, Staedke SG, et al. How experiences become data: the process of eliciting adverse event, medical history and concomitant medication reports in antimalarial and antiretroviral interaction trials. BMC Med Res Methodol. 2013;13:140.","journal-title":"BMC Med Res Methodol"},{"key":"3553_CR54","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1128\/AAC.48.11.4271-4280.2004","volume":"48","author":"K Stepniewska","year":"2004","unstructured":"Stepniewska K, Taylor WRJ, Mayxay M, Price R, Smithuis F, Guthmann J-P, et al. In vivo assessment of drug efficacy against Plasmodium falciparum malaria: duration of follow-up. Antimicrob Agents Chemother. 2004;48:4271\u201380.","journal-title":"Antimicrob Agents Chemother"},{"key":"3553_CR55","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1056\/NEJMc1612765","volume":"376","author":"F Lu","year":"2017","unstructured":"Lu F, Culleton R, Zhang M, Ramaprasad A, von Seidlein L, Zhou H, et al. Emergence of indigenous artemisinin-resistant Plasmodium falciparum in Africa. N Engl J Med. 2017;376:991\u20133.","journal-title":"N Engl J Med"},{"key":"3553_CR56","doi-asserted-by":"publisher","first-page":"e01818","DOI":"10.1128\/AAC.01818-18","volume":"63","author":"V Asua","year":"2019","unstructured":"Asua V, Vinden J, Conrad MD, Legac J, Kigozi SP, Kamya MR, et al. Changing molecular markers of antimalarial drug sensitivity across Uganda. Antimicrob Agents Chemother. 2019;63:e01818-e1918.","journal-title":"Antimicrob Agents Chemother"},{"key":"3553_CR57","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/s41591-020-1005-2","volume":"26","author":"A Uwimana","year":"2020","unstructured":"Uwimana A, Legrand E, Stokes BH, et al. Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat Med. 2020;26:1602\u20138.","journal-title":"Nat Med"},{"key":"3553_CR58","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0024-3205(85)90285-1","volume":"36","author":"FC Churchill","year":"1985","unstructured":"Churchill FC, Patchen LC, Campbell CC, Schwartz IK, Nguyen-Dinh P, Dickinson CM. Amodiaquine as a prodrug: importance of metabolite(s) in the antimalarial effect of amodiaquine in humans. Life Sci. 1985;36:53\u201362.","journal-title":"Life Sci"},{"key":"3553_CR59","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/sj.clpt.6100122","volume":"82","author":"S Parikh","year":"2007","unstructured":"Parikh S, Ouedraogo J-B, Goldstein JA, Rosenthal PJ, Kroetz DL. Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin Pharmacol Ther. 2007;82:197\u2013203.","journal-title":"Clin Pharmacol Ther"},{"key":"3553_CR60","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.pt.2008.01.006","volume":"24","author":"NJ White","year":"2008","unstructured":"White NJ, Stepniewska K, Barnes K, Price RN, Simpson J. Simplified antimalarial therapeutic monitoring: using the day-7 drug level? Trends Parasitol. 2008;24:159\u201363.","journal-title":"Trends Parasitol"},{"key":"3553_CR61","first-page":"1","volume":"13","author":"MK Omole","year":"2010","unstructured":"Omole MK, Onademuren OT. A survey of antimalarial drug use practices among urban dwellers in Abeokuta Nigeria. Afr J Biomed Res. 2010;13:1\u20137.","journal-title":"Afr J Biomed Res"},{"key":"3553_CR62","unstructured":"WHO. Levels and trends in child malnutrition. UNICEF\/WHO\/World Bank Group Joint Child Malnutrition Estimates. Key findings of the 2019 edition. https:\/\/www.who.int\/nutgrowthdb\/jme-2019-key-findings.pdf?ua=1. Accessed 5 Nov 2020."},{"key":"3553_CR63","doi-asserted-by":"crossref","unstructured":"WorldWide Antimalarial Resistance Network (WWARN) Lumefantrine PK\/PD Study Group. Artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient data. BMC Med. 2015;18:227. Erratum in: BMC Med. 2016;14 (1):214","DOI":"10.1186\/s12916-016-0757-5"},{"key":"3553_CR64","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1002\/cpt.1531","volume":"106","author":"P Chotsiri","year":"2019","unstructured":"Chotsiri P, Denoeud-Ndam L, Baudin E, Guindo O, Diawara H, Attaher O, et al. Severe acute malnutrition results in lower lumefantrine exposure in children treated with artemether-lumefantrine for uncomplicated malaria. Clin Pharmacol Ther. 2019;106:1299\u2013309.","journal-title":"Clin Pharmacol Ther"},{"key":"3553_CR65","first-page":"370","volume":"59","author":"S Fitoussi","year":"2009","unstructured":"Fitoussi S, Thang C, Lesauvage E, Barr\u00e9 J, Charron B, Filali-Ansary A, Lameyre V. Bioavailability of a co-formulated combination of amodiaquine and artesunate under fed and fasted conditions. A randomised, open-label crossover study. Arzneimittelforschung. 2009;59:370\u20136.","journal-title":"Arzneimittelforschung."},{"key":"3553_CR66","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/jcpt.12725","volume":"43","author":"OS Olawoye","year":"2018","unstructured":"Olawoye OS, Adeagbo BA, Bolaji OO. Moringa oleifera leaf powder alters the pharmacokinetics of amodiaquine in healthy human volunteers. J Clin Pharm Ther. 2018;43:626\u201332.","journal-title":"J Clin Pharm Ther"},{"key":"3553_CR67","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/clpt.2008.141","volume":"84","author":"SU Yasuda","year":"2008","unstructured":"Yasuda SU, Zhang L, Huang S-M. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther. 2008;84:417\u201323.","journal-title":"Clin Pharmacol Ther"},{"key":"3553_CR68","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S1473-3099(09)70320-2","volume":"9","author":"R Kerb","year":"2009","unstructured":"Kerb R, Fux R, M\u00f6rike K, Kremsner PG, Gil JP, Gleiter CH, et al. Pharmacogenetics of antimalarial drugs: effect on metabolism and transport. Lancet Infect Dis. 2009;9:760\u201374.","journal-title":"Lancet Infect Dis"},{"key":"3553_CR69","unstructured":"Medicines for Malaria Venture. 81-million-courses-seasonal-malaria-chemoprevention-delivered-countries. https:\/\/www.mmv.org\/our-impact\/achievements\/96-million-courses-seasonal-malaria-chemoprevention-delivered-13-countries. Accessed 5 Nov 2020"},{"key":"3553_CR70","unstructured":"World Medical Association. Declaration of Helsinki - Ethical Principles of Medical Research Involving Human Subjects 2013. https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects\/. Accessed 5 Nov 2020."},{"key":"3553_CR71","unstructured":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice, E6(R1) 1997. https:\/\/ichgcp.net. Accessed 5 Nov 2020."}],"updated-by":[{"DOI":"10.1186\/s12936-021-03651-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000}}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-020-03553-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-020-03553-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-020-03553-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T19:08:44Z","timestamp":1674846524000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-020-03553-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,6]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["3553"],"URL":"https:\/\/doi.org\/10.1186\/s12936-020-03553-6","relation":{"correction":[{"id-type":"doi","id":"10.1186\/s12936-021-03651-z","asserted-by":"object"}]},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,6]]},"assertion":[{"value":"3 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s12936-021-03651-z","URL":"https:\/\/doi.org\/10.1186\/s12936-021-03651-z","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The parent study was approved by the Ghana Health Service Ethical Review committee, the Navrongo Health Research Centre Institutional Review board (NHRCIRB) and Kintampo Health Research Centre Ethical Review Committee. The pharmacokinetic sub-study was approved by the University of Cape Town Faculty of Health Sciences Human Research Ethics Committee and the NHRCIRB. The study was conducted according to the ethical principles of the Declaration of Helsinki [], Good Clinical Practice [] and local ethical and regulatory requirements. Written informed consent was obtained from all patients aged 18\u00a0years or older prior to the performance of study related procedures, such as collection of blood samples for drug concentration measurements, filter paper for genotyping and urine samples for pregnancy tests. Informed consent was obtained from the parents or guardians of patients aged less than 18\u00a0years. In addition, assent was obtained from patients 12\u201317\u00a0years.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18"}}